Shares of 89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company surged in morning trading on Wednesday after announcing positive topline data from the Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In this study, patients dosed with 44mg every two weeks and 30mg weekly met both the primary histology endpoints with high statistical significance. Considering this positive data, pegozafermin will now advance to a Phase 3 trial.
Analysts are bullish about ETNB stock with a unanimous six Buys.